RxDoctor Payments Data

Jay Bitar, MD

Interventional Cardiology · Butte, MTNPI 1396795928

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Abiomed at 58.5% of the total. Reporting peaked in 2023 at $2,844 and has fallen 99.4% since, to $16 in 2024. That places this record below the midpoint for interventional cardiology clinicians in MT, where the typical reported total is $5,910.

$4,024in general payments, 2019–2025

Across 32 payments — averaging $125.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Penumbra, Inc.$613
  • Inari Medical, Inc.$294
  • Abbott$158
  • Shockwave Medical, Inc$124
  • Amgen$120
  • plus $361 from 6 others

What the payments were for

  • Travel & lodging$2,05751%
  • Food & beverage$1,96749%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,024 in reported general payments places this provider in the 45th percentile of 22 interventional cardiology providers in Montana.

See all interventional cardiology providers in Montana

Medicare billing

Part B allowed, 2024
$12,050
Medicare patients
110
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$42,890
XareltoRivaroxaban16$19,281
EntrestoSacubitril/Valsartan13$14,769
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$828
Potassium Chloride46$615
Atorvastatin Calcium49$581
Losartan Potassium78$572
Metoprolol Succinate51$550
Valsartan20$525
ClopidogrelClopidogrel Bisulfate42$521
Furosemide62$288
SotalolSotalol Hcl13$284
Labetalol Hcl16$248
Amlodipine Besylate31$183
Metoprolol Tartrate28$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$53$14,76913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 22 interventional cardiology providers in Montana.

Other interventional cardiology in Butte

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →